| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, ISO 9001, USP, BP |
| Suitable for: | Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Nootropics Raw Powder CAS 102767-28-2 Levetiracetam
| Product name:Levetiracetam Powder |
| Other Name: (S)-2-(2-Oxopyrrolidin-1-yl)Butanamide |
| Appearance:White Powder |
| CAS:102767-28-2 |
| M.F.:C8H14N2O2 |
| M.W.:170.20896 |
| Specification:99% |
Levetiracetam is an antiepileptic , which is mainly used for the combined treatment of partial seizures in adults and children over 4 years old.
Levetiracetam has been approved in the United States as add-on treatment for partial (focal), myoclonic, and tonic-clonic seizures. Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures, or as an adjunctive therapy for partial, myoclonic, and tonic-clonic seizures.Levetiracetam has been shown to reduce partial (focal) seizures by 50% or more as an add-on medication.It is also used in veterinary medicine for similar purposes. Based on low-quality evidence, levetiracetam is about as effective as phenytoin for prevention of early seizures
after traumatic brain injury.
Related Product
|
Product's Name
|
CAS
|
Purity
|
|
Nooglutyl
|
112193-35-8
|
99%
|
|
Noopept
|
157115-85-0
|
99%
|
|
Compound 7P
|
1890208-58-8
|
99%
|
|
Piracetam
|
7491-74-9
|
99%
|
|
Aniracetam
|
72432-10-1
|
99%
|
|
Nefiracetam
|
77191-36-7
|
99%
|
|
Pramiracetam
|
68497-62-1
|
99%
|
|
Oxiracetam
|
62613-82-5
|
99%
|
|
Fasoracetam
|
110958-19-5
|
99%
|
|
Sunifiram
|
314728-85-3
|
99%
|
|
Coluracetam
|
135463-81-9
|
99%
|
|
N-Methyl-D-aspartic acid(NMDA)
|
6384-92-5
|
99%
|
|
Alpha GPC(Choline Alfoscerate)
|
28319-77-9
|
99%
|
|
Alpha GPC(Choline Alfoscerate)
|
28319-77-9
|
50%
|
|
Citicoline
|
987-78-0
|
99%
|
|
Galantamine Hydrobromide
|
69353-21-5
|
99%
|
|
PRL-8-53
|
51352-87-5
|
99%
|
|
NSI-189 Phosphate
|
1270138-41-4
|
99%
|
|
NSI-189
|
1270138-40-3
|
99%
|
|
Tianeptine
|
66981-73-5
|
99%
|
|
Tianeptine sodium
|
30123-17-2
|
99%
|
|
Tianeptine hemisulfate monohydrate (THM)
|
1224690-84-9
|
99%
|
|
J-147
|
1146963-51-0
|
99%
|
| ITEM | SPECIFICATION | RESULT | METHOD |
| Appearance | White powder, neutral odor, highly hygroscopic | Conforms | Visual |
| Identification | Standard solution and test solution same spot,RF | Conforms | TLC |
| Specific Optical | -2.4°~ -2.8° | -2.72° | |
| Heavy metals (as PB) | ≤10ppm | Conforms | AAS |
| Sulfate (SO4) | ≤0.02% | Conforms | Colorimetry |
| Chloride (Cl) | ≤0.02% | Conforms | Colorimetry |
| Phosphate Ion (P) | ≤5ppm | Conforms | Colorimetry |
| Residual solvent(ethanol) | ≤1.0% | Conforms | HS-GC |
| pH | 4.5~7.0 | 5.10 | |
| Related substance | Spot not bigger than standard solution spot | No spot | TLC |
| Water Content | ≤2% | 0.26% | KF |
| Assay (dried basis) | 98.0%--102.0% | 99.48% | Potentiometric titration |
| Assay (dried basis) | 98.5%--100% | 99.2% | HPLC |
Function:
Levetiracetam is an antiepileptic , which is mainly used for the combined treatment of partial seizures in adults and children over 4 years old.
Levetiracetam has been approved in the United States as add-on treatment for partial (focal), myoclonic, and tonic-clonic seizures. Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures, or as an adjunctive therapy for partial, myoclonic, and tonic-clonic seizures.Levetiracetam has been shown to reduce partial (focal) seizures by 50% or more as an add-on medication.It is also used in veterinary medicine for similar purposes. Based on low-quality evidence, levetiracetam is about as effective as phenytoin for prevention of early seizures
after traumatic brain injury.
Application:
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}